Two endpoints of genetic toxicity, mutation at the X-linked Pig-a gene and chromosomal damage in the form of micronucleated reticulocytes (MN-RETs), were evaluated in blood samples obtained from 28-day repeat-dosing studies typical of those employed in toxicity evaluations. Male Wistar Han rats were treated at 24-h intervals on days 1 through 28 with one of five prototypical genotoxicants: N-ethyl-N-nitrosourea, 7,12-dimethyl-12-benz[a]anthracene, 4-nitroquinoline-1-oxide (4NQO), benzo(a)-pyrene, and N-methyl-N-nitrosourea. Flow cytometric scoring of CD59-negative erythrocytes (indicative of glycosylphosphatidylinositol anchor deficiency and hence Pig-a mutation) was performed using blood specimens obtained on days 21, 15, 29, and 56. Blood specimens collected on days 4 and 29 were evaluated for MN-RET frequency using flow cytometry-based MicroFlow Kits. With the exception of 4NQO, each chemical induced significant increases in the frequency of MN-RETs on days 4 and 29. All five agents increased the frequency of mutant phenotype (CD59 negative) reticulocytes (RETs) and erythrocytes. Mutation responses in RETs occurred earlier than in erythrocytes and tended to peak, or nearly peak, at day 29. In contrast, the mutant phenotype erythrocyte responses were modest on day 29 and required additional time to reach their maximal value. The observed kinetics were expected based on the known turnover of RETs and erythrocytes. The data show that RETs can serve as an appropriate indicator cell population for 28-day studies. Collectively, these data suggest that blood-based genotoxicity endpoints can be effectively incorporated into routine toxicology studies, a strategy that would reduce animal usage while providing valuable genetic toxicity information within the context of other toxicological endpoints.
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Integration of genotoxicity endpoints into repeat-dosing toxicity studies has several potential benefits. In addition to reducing the number of animals needed for safety assessment purposes, the genotoxicity results are expected to be more informative and interpretable when obtained in the context of general toxicology, metabolic, and pharmacokinetic studies (Blakey et al., 2008; Hamada et al., 2001; Krishna et al., 1998) .
While integration of genotoxicity endpoints is clearly attractive, and is encouraged in a number of guidance documents and other reports (International Conference on Harmonization, 2008; Pfuhler et al., 2009 ; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 2006) , practical obstacles to implementation exist. These are most pronounced in the case of assessment of gene mutation. Although transgenic animal models exist that allow measurement of mutant cell frequencies in virtually any tissue, their requirement for nonstandard rodent strains has hindered utilization of these systems for integrated studies. The endogenous Hprt gene mutation assay can be performed with standard laboratory animals, but its resource-intensive nature and limitation to tissues amenable to in vitro cell culture are significant barriers to widespread adoption. This laboratory has previously described automated approaches for determining in vivo mutation frequencies at the endogenous Pig-a gene locus that overcome many of these practical issues , Phonethepswath et al., 2008 . This system utilizes flow cytometry to quantify mutant cells based on the glycosylphosphatidylinositol (GPI) anchor-deficient phenotype, a strategy first proposed by Luzzatto and colleagues (Araten et al., 1999) . Our proof-ofprinciple experiments have focused on identification of mutant phenotype erythrocytes in mouse and rat blood specimens. Dobrovolsky et al. (2010) and Miura et al. (2008a,b) have successfully applied similar flow cytometric scoring strategies to the analysis of mutant phenotype rat erythrocytes and splenic lymphocytes.
Recently, we described the kinetics by which mutant phenotype rat erythrocytes (i.e., CD59 negative, abbreviated RBC CD59À ) and mutant phenotype reticulocytes (RETs) (i.e., CD59 negative, abbreviated RET CD59À ) enter and are eliminated from the circulation after exposure to prototypical mutagens (Phonethepswath et al., 2010) . These data indicated that mutant phenotype RETs and erythrocytes induced by some agents persist in peripheral blood for considerable periods of time, demonstrating that uncommitted hematopoietic stem/ progenitor cells can continue to produce GPI anchor-deficient cells for at least 6 months. Those characteristics suggested that the assay would be highly compatible with subchronic and chronic toxicity studies, as mutants should accumulate with repeated dosing. Therefore, one objective of the current studies was to evaluate the sensitivity of the Pig-a assay in the context of the commonly conducted 28-day repeat-dosing study design.
A second objective was to assess the sensitivity of the rat peripheral blood micronucleated RET (MN-RET) endpoint in the context of a 28-day treatment schedule. Several published reports support the concept that this endpoint of cytogenetic damage can be integrated into routine toxicology studies (Hamada et al., 2001; MacGregor et al., 2006) . However, as reflected by language that appears in the proposed International Conference on Harmonization Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use S2(R1) (2008), some concerns persist over the sensitivity of the assay when exposures occur at relatively low-dose levels for protracted periods of time (as compared to short-term acute studies using higher exposure levels). Data presented herein are discussed with this concern in mind.
MATERIALS AND METHODS

Reagents
Sesame oil, 7, anthracene (DMBA; CAS no. 57-97-6), benzo(a)pyrene (B(a)P; CAS no. 50-32-8), 4-nitroquinoline 1-oxide (4NQO; CAS no. 56-57-5), and methylcellulose were purchased from Sigma-Aldrich, St Louis, MO. N-methyl-N-nitrosourea (MNU; CAS no. 684-93-5) was from Pfaltz & Bauer, Waterbury, CT. PBS (phenol red and divalent cation free) was from Mediatech, Inc., Herndon, VA. Heparin solution and all reagents necessary to perform the micronucleus analyses as described herein were from In Vivo Rat MicroFlow PLUS Kits (v090203, Litron Laboratories, Rochester, NY). Lympholyte-Mammal cell separation reagent was purchased from CedarLane, Burlington, NC (CAT no. CL5110). Anti-rat CD59, clone TH9, was custom-conjugated to phycoerythrin by BD Biosciences, San Jose, CA. SYTO 13 was purchased from Invitrogen, Carlsbad, CA (CAT no. S-7575). Proaerolysin was purchased from the University of Saskatchewan, Saskatoon, Canada.
Studies with Aerolysin
Experiments were performed to test the assumption that the CD59-negative phenotype is a reliable indicator of GPI anchor deficiency. These experiments utilized the toxin aerolysin, a high-affinity GPI anchor ligand that causes cell lysis (Diep et al., 1998) . In one representative experiment, 7-to 8-week-old male Wistar rats were treated with ENU on three consecutive days via oral gavage (40 mg/kg/day). Three weeks after the final administration, blood was collected, leukodepleted, and stained for Pig-a analysis as described below. The numbers of CD59-positive and CD59-negative erythrocytes collected over a 6-min data acquisition period were recorded (i.e., time zero values). This same stained blood specimen was exposed to 0.75 lg aerolysin and incubated at 37°C. At 30-min intervals, the numbers of CD59-positive and CD59-negative erythrocytes were determined for 6-min data acquisition periods. These values were converted to a percentage of the time zero measurements. Note that just before use, proaerolysin was converted to aerolysin with trypsin according to manufacturer's recommendations.
Animals, Treatments, and Blood Collection
Experiments were conducted with the oversight of the University of Rochester's Institutional Animal Care and Use Committee. Male Wistar Han rats were purchased from Charles River Laboratories, Wilmington, MA. Rodents were allowed to acclimate for~1 week before treatment. Water and food were available ad libitum throughout the acclimation and experimental periods. For the 28-day studies, each treatment group consisted of five randomly selected rats, age 7-8 weeks at the start of treatment, and each experiment included a concurrent vehicle control group. All treatments were via oral gavage in a volume of 10 ml/kg body weight. Test articles were administered at intervals of~24 h on 28 consecutive days (days 1-28). Dose levels, vehicles employed, and other information are summarized in Table 1 .
Blood specimens were collected from each animal on days À1, 15, 29, and 56. The samples obtained on day 29 (24 h after the last administration) are particularly important because this is the usual day of termination of 28-day toxicity studies. The significance of day 56 blood specimens (4 weeks after the last administration) is related to the fact that recovery animals are often included in 28-day studies, and the in-life portion is usually terminated between 2 and 4 weeks after the last treatment. Blood was obtained by nicking a lateral tail vein with a surgical blade after animals were warmed briefly under a heat lamp. Approximately 50-100 ll of free-flowing blood were collected directly into heparinized capillary tubes (Fisher Scientific, . Immediately upon collection, 30 ll of each blood specimen were transferred to tubes containing 100 ll heparin solution (500 units/ml PBS) where they remained at room temperature for less than 2 h, after which time they were either immediately leukodepleted as described below or stored at 4°C until leukodepletion (within 1 h).
Cell Staining: Pig-a
The blood processing steps for Pig-a mutation scoring have been described in detail elsewhere (Phonethepswath et al., 2010) . Briefly, each whole-blood/ heparin specimen was leukodepleted with Lympholyte solution. At this stage, the resulting erythrocyte-enriched samples were immediately transferred to tubes that contained saturating phycoerythrin (PE) conjugated anti-CD59 or else stored at 4°C for later ( 24 h) staining and analysis. After removing unbound antibody through centrifugation, cells were resuspended with 1 ml working nucleic acid dye solution (SYTO 13). After incubating for 30 min at 37°C, samples were placed on ice until flow cytometric analysis (within~2 h).
Instrument Calibration Standard: Pig-a
On each day of analysis, an instrument calibration standard was prepared by creating a specimen with~50% wild-type cells and 50% mutant-mimicking cells. The procedure for generating this specimen has been described previously (Phonethepswath et al., 2010) . The resulting instrument calibration standard provided sufficient numbers of red blood cells (RBCs) that exhibited a full range of PE and SYTO 13 fluorescence intensities that were useful for optimizing photomultiplier tube voltages and fluorescence compensation settings on a daily basis. The position of the CD59-negative cells also provided a rational approach for defining the vertical demarcation line used to distinguish mutant cells from wild-type cells. See RBCs per specimen ( 5 min). As these forward scatter-triggered analyses acquired 1 3 10 6 RBCs per specimen, they also provided a means to determine the frequency of RETs among total RBCs.
For determination of the frequency of RET CD59À , the fluidics rate was set to medium and the data acquisition trigger was set on SYTO 13-associated fluorescence. This SYTO 13 threshold value was set sufficiently high such that the majority of RBCs (i.e., mature erythrocytes that lack RNA) were eliminated from consideration. See Figure 1 , panel C. This strategy reduced file sizes and also allowed for a greater flow rate, making it possible to evaluate between 0.3 and 1 3 10 6 RETs per specimen in 15 min.
Micronucleus Assay, Cell Staining, and Data Acquisition
Determinations of the frequency of MN-RET were performed using blood specimens collected on days 4 and 29 with a FACSCalibur flow cytometer providing 488-nm excitation. The necessary reagents and instructions for use were from In Vivo Rat MicroFlow PLUS Kits and are described in detail elsewhere (Dertinger et al., 2004; Torous et al., 2003) . Kit-supplied malariainfected erythrocytes served as biological standards and guided instrument settings on each day of analysis (Dertinger et al., 2000; Tometsko et al., 1993) . The frequency of MN-RET was determined upon the acquisition of~20,000 CD71-positive RETs per blood sample.
Calculations and Statistical Analyses
Calculations of frequency, average, SEM, and arcsine square-root transformations were performed with Excel Office X for Mac (Microsoft, Seattle, WA). All statistical tests described below were two sided and used p < 0.05 to indicate significance.
Pig-a assay. The frequency of mutant phenotype RBCs is expressed as the number of RBC CD59À per 1 million total RBCs. The frequency of mutant phenotype RETs is expressed as the number of RET CD59À per 1 million total RETs. For graphical presentations, RET values for each mutagen-treated group are expressed as a percentage of the mean vehicle control value at that same time point.
Pig-a data were analyzed with SAS (v9.1) and Matlab (v2008a). The primary endpoints included the frequency of RETs among RBCs, the frequency of RET CD59À among RETs, and the frequency of RBC CD59À among RBCs as measured by flow cytometry. The effect of treatment on each endpoint was considered at each individual time point using the nonparametric KruskalWallis test, and pairwise comparisons based on the Wilcoxon rank sum test were performed to evaluate vehicle against each of the other treatment groups. Additionally, in order to assess the overall significance of treatment effect across time points, the p values obtained either from the Kruskal-Wallis tests or from the Wilcoxon rank sum tests (days 15 through 56) were combined using Fisher's combination method. The associated (overall) p value was computed using a permutation approach. This was done separately for each endpoint and for RBC CD59À and RET CD59À jointly. Finally, mixed effects models, including a random intercept that modeled the between-experiment variability, were used to describe values of the endpoints at baseline and to compute 95% confidence intervals for the mean measurement.
Micronucleus assay. The proportion of MN-RET among RETs was transformed in Excel as follows: transformed data ¼ asin(sqrt(proportion of MN-RET)). One-way ANOVA was used to evaluate the effect of treatment on these transformed MN-RET proportions (JMP software, v5.0 for Mac). If p < 0.05, each treatment group was compared to vehicle control using Dunnett's multiple comparison t-test. These analyses were performed separately for specimens obtained on day 4 and day 29.
RESULTS
Aerolysin Treatment
Results of a representative aerolysin experiment are shown in Figure 2 . As aerolysin exposure time increased, fewer intact CD59-positive erythrocytes remained. These cells were presumably sensitive to aerolysin because they expressed GPI anchors. CD59-negative erythrocytes remained intact over this same time frame, presumably because they lacked GPI anchors. These data support the underlying premise of this erythrocyte-based mutation assay-that the CD59-negative phenotype is a reliable reporter of GPI anchor deficiency. The results also reinforce the appropriateness of the cell staining strategy utilized for the definitive studies described below.
Overview of Definitive Studies
As shown in Table 2 , each chemical affected weight gain markedly. This was most pronounced with MNU, where animals lost nearly 9 g on average. In conjunction with information gathered during preliminary dose range finding studies and/or outward signs of toxicity noted during the definitive studies (outlined in Table 1 ), these data suggest that maximum tolerated doses were either reached or approached.
Data compiled from each of the 100 Wistar rat specimens collected on the day prior to treatment (20 rats per study 3 5 studies) are provided in Table 3 . These data demonstrate consistent low spontaneous mutant frequency values, an important requirement when such extremely rare events are being scored.
RET CD59À and RBC CD59À frequencies were elevated significantly following treatment with each of the five mutagenic chemicals studied (p < 0.05). All p values associated with these Pig-a assay determinations are reported in a Supplementary data file. With the exception of 4NQO, each chemical increased MN-RET frequency significantly.
N-ethyl-N-nitrosourea
Frequencies of RETs, RET CD59À , RBC CD59À , and MN-RET following treatment with ENU are shown in Figure 3 . RET frequencies were modestly reduced by the high dose of ENU at the day 15 time point, with evidence of a rebound effect thereafter. RET CD59À values were markedly increased, with 
N-methyl-N-nitrosourea
Frequencies of RETs, RET CD59À , RBC CD59À , and MN-RET following treatment with MNU are shown in Figure 4 . RET frequencies were modestly reduced by the high dose of MNU at the day 15 time point, with evidence of a rebound effect thereafter. RET CD59À values were elevated between days 15 and 56, with the highest values tending to occur on day 29. As with ENU treatment, the most substantial MNU-induced RBC CD59À responses occurred between days 29 and 56. MNU induced robust dose-related increase in micronucleus frequency on days 4 and 29. The level of MN-RET induction was markedly higher for MNU compared to ENU, even though ENU treatment generated much higher yields of mutant phenotype cells. INTEGRATED PIG-A MUTATION AND MICRONUCLEUS ASSAYS 405 frequencies were markedly reduced by the high-dose level on days 15 and 29. Outward signs of toxicity for this group became pronounced on days 30 and 31 and stopped further investigation of these rats at that time. RET CD59À values were elevated between days 15 and 56, with maximal values observed by day 29. Induced RET CD59À values for the low-and mid-dose groups remained stable until the day 56 time point. Elevated RBC CD59À frequencies were evident on day 29, reaching maximal values on day 56. Mean MN-RET frequencies were elevated in the high-dose group on days 4 and 29, with a more robust increase observed at the later time point.
4-Nitroquinoline-1-oxide
Frequencies of RETs, RET
CD59À
, RBC CD59À , and MN-RET following treatment with 4NQO are shown in Figure 6 . Whereas treatment markedly affected weight gain, RET frequencies were not affected by 4NQO. One animal in the high-dose group was severely moribund on day 30; therefore, the group size was reduced to four thereafter. The high-dose treatment significantly increased RET CD59À values on days 15 through 56. While the mid-dose group consistently exhibited modestly higher RET CD59À frequencies compared to control, the effect did not reach statistical significance. 4NQO increased RBC CD59À frequencies slightly, an effect that was also restricted to the high-dose group. Note that data for one highdose animal, Q14, were not graphed at day 56 or considered in the statistical analyses at that time point. This is because the Q14 sample at day 56 exhibited extremely discrepant RET CD59À and RBC CD59À values (e.g., RET CD59À ¼ 1587 3 10 À6 in the case of Q14 vs. 16.6 3 10 À6 for the remaining animals in this group). The most likely explanation for this result at this time is clonal expansion of an early progenitor/ stem cell. Interestingly, even though Pig-a mutation was evident in the erythroid lineage, no significant effect on MN-RET frequency was observed for 4NQO. frequencies were elevated in exposed animals, especially in high-dose animals on day 29. It is not clear at this time how temporary stimulation of erythropoiesis might affect the yield of mutant phenotype cells (RET frequencies were back to control levels on day 56). RET CD59À values were elevated between days 15 and 56. While the greatest mean RET CD59À value for the high-dose group was exhibited on day 56, the frequency was only slightly lower at day 29. As with the other agents, RBC CD59À responses continued to rise between days 29 and 56. B(a)P caused dose-related increases in MN-RET on days 4 and 29.
Benzo(a)pyrene
Acute Versus Protracted Dosing: Pig-a RET CD59À frequencies resulting from 28 days or 3 days of treatment with similar total doses of ENU are presented in Figure 8 . The data for the 3-day treatments are from a previous study in our laboratory that also utilized male Wistar rats (same animal supplier, age at time of treatment, sample handling protocols, etc.) (Phonethepswath et al., 2010) . Given how closely the maximal RET CD59À values compare across these acute and highly fractionated administration schedules, these data suggest that mutant phenotype cells can accumulate in a nearly additive fashion with repeat dosing, at least in the case of some chemicals like ENU. Figure 9 shows MNU-induced RET CD59À frequencies obtained in the current 28-day study along with values derived from a previous study from our laboratory that used a 3-day treatment schedule (same animal supplier, age at time of treatment, sample handling protocols, etc.) (Phonethepswath et al., 2010) . Unlike ENU, MNU was not additive throughout the dose range examined, as fractionation of 140 and even 280 mg/kg did not approach RET CD59À frequencies induced by 90 mg/kg delivered over 3 days.
DISCUSSION
Each of the five mutagenic agents studied herein increased the frequency of GPI anchor-deficient erythroid cells. Both the total RBC population and the RET subpopulation exhibited increased mutant phenotype cell frequencies, especially at the days 29 and 56 time points. However, in the standard conduct of a 28-day study, the majority of animals are not available past day 29. For this reason, the RET cohort is the appropriate cell population in which to monitor the mutant cell phenotype, as RET CD59À responses are maximal or nearly so by day 29. RBC CD59À responses require a significantly longer manifestation time.
The persistence of GPI anchor-deficient hematopoietic cells reported here and elsewhere Miura et al., 2009) suggests that Pig-a mutation is a neutral or nearly neutral event, meaning the affected cells are not highly selected for or against. Neutrality predicts that mutant cells should accumulate with repeat dosing, a desirable characteristic of transgenic rodent models, but not of most other in vivo genotoxicity endpoints (Heddle et al., 1995) . Miura et al. (2009) demonstrated accumulation of ENU-induced Pig-a mutant cells with repeat dosing, and the acute versus highly fractionated ENU data presented herein support that finding. However, it is apparent that additivity of Pig-a mutant yield is agent specific and does not always occur throughout the range of doses that are effective at inducing mutation. This is well illustrated by MNU. In a previous report of MNU administration over 3 days, two observations are inconsistent with additivity: the 45-mg/kg dose led to considerably less than one-half the response induced by 90 mg/kg and the frequency of RET CD59À dropped dramatically between days 15 and 30 time points.
We previously speculated that the extreme persistence of ENU-induced RET CD59À frequencies was due to mutation in hematopoietic stem cells (Phonethepswath et al., 2010) , whereas the fall-off of MNU-induced RET CD59À indicates targeting of committed progenitors that lack self-renewal capacity. These characteristics of the 3-day study data suggest that protracted administrations of MNU would not yield maximal mutant frequencies consistent with the prediction of additivity of the individual doses. Data described herein are consistent with this reasoning, as rats exposed to a total dose of 140 and even 280 mg/kg over 28 days exhibited a slight response compared to the results obtained from the 3-day exposure to 90 mg/kg. One possible explanation is that DNA repair capacity can be overwhelmed by high-dose levels of MNU, whereas repair can occur more efficiently when similar exposures are fractioned over time.
Given the kinetics of MN-RET appearance and disappearance from the circulation, which are determined by the short half-life of RETs and the strong selective pressure against cells that express micronuclei, the yield of MN-RET does not generally increase with repeat dosing (Hamada et al., 2001 ). Thus, it was expected that similar MN-RET frequencies would be observed on days 4 and 29. DMBA-induced MN-RET is an obvious exception in the present study. Induced metabolism and/or bioaccumulation may explain this result.
Two other observations related to the MN-RET frequencies observed in the present studies are worth noting. B(a)P was observed to induce MN-RET in a dose-dependent manner on days 4 and 29, a result that differs from the negative findings reported by Hamada et al. (2001) following 28 days of treatment. With 4NQO, high acute doses were previously shown to induce micronuclei (Phonethepswath et al., 2010) , but the doses used herein did not significantly affect the frequency of MN-RET. The fivefold lower 4NQO dosage per day likely explains this result. Collectively, these data support the integration of the MN-RET endpoint into repeat-dosing toxicology studies, recognizing that in some cases acute exposures to higher doses may be more genotoxic.
The cytogenetic damage and mutation endpoints described herein were collected very efficiently due to the direct application of high-throughput scoring methods to small samples of peripheral blood. Processing of blood specimens and flow cytometric analyses of both endpoints generally required 1.5 technicians working approximately two full days per chemical per time point. Importantly, the expression time for mutant RET frequencies were found to be compatible with the standard conduct of 28-day toxicity studies, making it practical for the first time to integrate both mutation and cytogenetic damage measurements without the need for nonstandard rodents or harvest times or the necessity of cell culture to express mutations.
With more extensive validation of the Pig-a endpoint, experimental designs such as the one(s) described herein have the potential to significantly reduce the number of dedicated in vivo genotoxicity studies required, while at the same time improving the extent and value of available genotoxicity information. A number of laboratories are currently involved in assay validation efforts that have been designed to address the most critical data gaps that currently exist, especially (1) assessment of assay portability, (2) studies of additional mutagenic and nonmutagenic agents, (3) determination of consensus statistical approaches for analyzing Pig-a data, (4) DNA sequencing in order to firmly establish the link between GPI anchor deficiency with bona fide Pig-a mutation, (5) evaluation of the erythrocyte assay's cross-species potential, and (6) determination of whether the GPI anchor-deficient phenotype can be used to study mutation in nonerythroid cells, e.g., primary hepatocytes.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci .oxfordjournals.org/. Dobrovolsky, Jan van Benthem, and Jennifer Sasaki-who shared valuable advice, especially in regard to choice of chemicals and dose levels. Disclosure: several of the authors are employed by Litron Laboratories, a company that sells MicroFlow Kits that can be used to score rodent MN-RET frequencies as described herein; J. MacGregor, J. Palis, and O. Hyrien serve as consultants to Litron Laboratories under the NIEHS-funded grant; Litron Laboratories has filed patent applications that relate to mutation measurements based on the GPI anchor deficiency phenotype as a means to quantify Pig-a gene mutation frequency.
